Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with world health organization grade 2 oligodendroglioma

Cancer

Volumn 88, Issue 4, 2000, Pages 862-869

  Reis Filho, Jorge S ^a   Faoro, Leonardo N ^a   Carrilho, Caria ^b   Bleggi Torres, Luiz F ^a   Schmitt, Fernando C ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Bcl 2; Brain tumors; Epidermal growth factor receptor; Immunohistochemistry; MIB 1; Oligodendroglioma; Prognosis; Proliferating cell nuclear antigen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MITOSIS; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; OLIGODENDROGLIOMA; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0034651524     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000215)88:4<862::AID-CNCR17>3.0.CO;2-G     Document Type: Article

References (27)

1. Kleihues P, Cavenee WK. Pathology and genetics of tumors of the nervous system. 1st ed. Lyon: International Agency for Research, 1998.
2. Dehghani F, Schachenmayr W, Laun A, Korf HW. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berlin) 1998;95:493-504.
3. Heegaard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995;76:1809-13.
4. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996;78:1107-13.
5. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997;41:878-84.
6. Stemmer-Rachamimov AO, Louis DN. Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 1997;9:230-4.
7. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. 2nd ed. Berlin: Springer-Verlag, 1993.
8. Coons SW, Pearl DK. Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer 1998;82: 1550-5.
9. Conover WJ. Practical nonparametric statistics. 3rd ed. Wiley, John & Sons, Inc., 1998.
10. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York: Wiley-Liss, Inc., 1992.
11. Siegel S. Nonparametric Statistics. 1st ed. New York: McGraw-Hill Book Company, Inc., 1956.
12. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 1989; 115:179-88.
13. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
14. Sharma S, Karak AK, Singh R, Mehta VS, Sarkar C, Schmitt HP. A correlative study of gliomas using in vivo bromode-oxyuridine labeling index and computer-aided malignancy grading. Pathol Oncol Res 1999;5:134-41.
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
16. Bravo R. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp Cell Res 1986;162: 287-93.
17. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
18. Schmitt FC, Ferreira MP. MIB-1 is a suitable marker of proliferative activity in formalin-fixed, paraffin-embedded sections of breast cancer. Int J Surg Pathol 1995;2:287-94.
19. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996; 149:29-35.
20. Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I, et al. Epidermal growth factor receptor-dependent transformation by a human EGF receptor proto-oncogene. Science 1987;238:1408-10.
21. Fuller GN, Bigner SH. Amplified cellular oncogenes in neoplasms. Mutat Res 1992;276:299-306.
22. Wong AJ, Zoltick PM, Moscatello DK. The molecular biology and molecular genetics of astrocytic neoplasms. Semin Oncol 1994;21:139-48.
23. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83:5114-8.
24. Nakasu S, Nakasu I, Nioka H. bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 1994;88:520-6.
25. Ellison DW, Steart PV, Gatter KC. Apoptosis in cerebral astrocytic tumors and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995; 21:352-61.
26. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, et al. Prognostic factors in oligodendroglioma. Can J Neural Sci 1997;24:313-9.
27. Schiffer D, Dutto A, Cavalla P, Chio A, Migheli A, Piva R. Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem Int 1997;31:245-50.